Freeline Therapeutics Holdings plc – NASDAQ:FRLN
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Freeline Therapeutics Holdings stock price monthly change
+0.94%
month
Freeline Therapeutics Holdings stock price quarterly change
+51.77%
quarter
Freeline Therapeutics Holdings stock price yearly change
+1031.58%
year
Freeline Therapeutics Holdings key metrics
Market Cap | 28.28M |
Enterprise value | N/A |
P/E | -0.2 |
EV/Sales | N/A |
EV/EBITDA | 0.39 |
Price/Sales | N/A |
Price/Book | 0.24 |
PEG ratio | N/A |
EPS | -11.46 |
Revenue | N/A |
EBITDA | -84.21M |
Income | -49.93M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFreeline Therapeutics Holdings stock price history
Freeline Therapeutics Holdings stock forecast
Freeline Therapeutics Holdings financial statements
| Dec 2022 | 0 | -22.99M | |
|---|---|---|---|
| Mar 2023 | 0 | 1.16M | |
| Jun 2023 | 617K | -16.01M | -2594.98% |
| Sep 2023 | 5K | -12.08M | -241760% |
| 2025 | 44.55M | -27.54M | -61.83% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 86641000 | 34.22M | 39.5% |
|---|---|---|---|
| Mar 2023 | 81366000 | 25.38M | 31.19% |
| Jun 2023 | 62653000 | 20.63M | 32.94% |
| Sep 2023 | 49219000 | 19.17M | 38.97% |
| Dec 2022 | -19.85M | -3.89M | 88K |
|---|---|---|---|
| Mar 2023 | -18.44M | 23.81M | -91.82K |
| Jun 2023 | -17.27M | -194K | 32K |
| Sep 2023 | -8.67M | -6K | 39.18K |
Freeline Therapeutics Holdings alternative data
| Aug 2023 | 152 |
|---|---|
| Sep 2023 | 152 |
| Oct 2023 | 152 |
| Nov 2023 | 152 |
| Dec 2023 | 152 |
| Jan 2024 | 152 |
| Feb 2024 | 152 |
| Mar 2024 | 152 |
| Apr 2024 | 152 |
| May 2024 | 152 |
| Jun 2024 | 152 |
| Jul 2024 | 152 |
Freeline Therapeutics Holdings other data
46.58%
-19.74%
of FRLN is owned by hedge funds
27.61M
-10.44M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q2 2023 15 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 4 Apr 2023 | Q4 2022 Earnings Call Transcript |
-
When is Freeline Therapeutics Holdings's next earnings date?
Unfortunately, Freeline Therapeutics Holdings's (FRLN) next earnings date is currently unknown.
-
Does Freeline Therapeutics Holdings pay dividends?
No, Freeline Therapeutics Holdings does not pay dividends.
-
How much money does Freeline Therapeutics Holdings make?
Freeline Therapeutics Holdings has a market capitalization of 28.28M.
-
What is Freeline Therapeutics Holdings's stock symbol?
Freeline Therapeutics Holdings plc is traded on the NASDAQ under the ticker symbol "FRLN".
-
What is Freeline Therapeutics Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Freeline Therapeutics Holdings?
Shares of Freeline Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Freeline Therapeutics Holdings have?
As Jul 2024, Freeline Therapeutics Holdings employs 152 workers.
-
When Freeline Therapeutics Holdings went public?
Freeline Therapeutics Holdings plc is publicly traded company for more then 5 years since IPO on 7 Aug 2020.
-
What is Freeline Therapeutics Holdings's official website?
The official website for Freeline Therapeutics Holdings is freeline.life.
-
How can i contact Freeline Therapeutics Holdings?
Freeline Therapeutics Holdings can be reached via phone at +44 1438 906870.
Freeline Therapeutics Holdings company profile:
Freeline Therapeutics Holdings plc
freeline.lifeExchange:
NASDAQ
Full time employees:
152
Industry:
Biotechnology
Sector:
Healthcare
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Stevenage Bioscience Catalyst
Stevenage, SG1 2FX
Stevenage, SG1 2FX
CIK: 0001810031
ISIN: US35655L1070
CUSIP: 35655L107
